Healthcare Industry Developments | BioTuesdays by Kilmer Lucas IR

Developments

AMA approves code for Plus’ CNSide CSF TCE test

Plus Therapeutics (NASDAQ: PSTV) has announced that the American Medical Association (AMA) has approved a new proprietary laboratory analyses (PLA) Current Procedural Terminology (CPT) code for its CNSide Cerebrospinal...

April 7, 2026

Developments

UACC initiates study of Fennec’s PEDMARK for AYA and adult cancers

Fennec Pharmaceuticals (NASDAQ: FENC; TSX: FRX) has announced the initiation of an investigator-sponsored study by University of Arizona Cancer Center (UACC) to evaluate use of PEDMARK, a sodium thiosulfate injection...

April 7, 2026

Developments

NervGen completes EOP2 meeting and aligns with FDA on Phase 3 study

NervGen Pharma (NASDAQ: NGEN) has announced the completion of a successful end-of-Phase 2 (EOP2) meeting with the FDA and alignment on RESTORE, the company’s Phase 3 registrational study designed to evaluate NVG-291 for...

April 7, 2026

Developments

Vyome to present compelling data on treatment for MFW at AACR

Vyome Holdings (NASDAQ: HIND) has announced it will present its full Phase 2 investigator-initiated study results and preclinical data supporting the efficacy and safety of VT-1953 as a potential treatment for malodor...

April 6, 2026

Developments

Medicus submits study design to FDA for Teverelix in AURr

Medicus Pharma (NASDAQ: MDCX) has submitted an optimized Phase 2 clinical study design to the FDA for Teverelix, its investigational GnRH antagonist, for the prevention of recurrent acute urinary retention (AURr) in men...

April 6, 2026

Developments

FDA clears Stereotaxis’ Synchrony system

Stereotaxis (NYSE: STXS) has received FDA 510(k) clearance for its Synchrony system, designed to digitize and modernize the interventional cath lab. According to Stereotaxis, Synchrony is made available with SynX, a...

April 6, 2026

Developments

PureTech’s Seaport reports positive data from trial of GlyphAgo in GAD

PureTech Health (NASDAQ: PRTC; LSE: PRTC) has announced that its founded entity, closely held Seaport Therapeutics, has reported positive proof of concept topline data from portions of its ongoing Phase 1 proof-of...

April 2, 2026

Developments

Adagene and Incyte collaborate to evaluate combination therapy in MSS CRC patients

Adagene (NASDAQ: ADAG) and Incyte (NASDAQ: INCY) have announced a clinical collaboration to evaluate the combination of muzastotug (ADG126) and INCA33890, a TGFβR2 × PD-1 bispecific antibody, in patients with...

April 2, 2026

Developments

EBMT journal publishes findings from MaaT’s CHRONOS study in 3L aGvHD

MaaT Pharma (EURONEXT: MAAT) announced the publication of CHRONOS, a large, multicenter, retrospective cohort study evaluating real-world outcomes of third-line (3L) systemic therapies, excluding microbiotherapy, in 59...

April 1, 2026

Developments

Cereno reports positive data from CS1 treatment in PAH

Cereno Scientific (NASDAQ First North: CRNO B) has announced initial learnings from its 12-month expanded access program with lead candidate, oral, once-daily CS1, in pulmonary arterial hypertension (PAH), confirming...

March 31, 2026

Developments

BioVersys enters agreement with HMH to develop ansamycin

BioVersys (SIX: BIOV) has entered into an exclusive ansamycin drug discovery collaboration and license agreement with Hackensack Meridian Health (HMH), a U.S.-based private nonprofit health system, to jointly profile...

March 31, 2026

Developments

Idorsia highlights positive results from study of DORA in pediatric patients with insomnia

Idorsia (SIX: IDIA) has announced positive top-line results from its Phase 2 dose-finding study evaluating 10, 25, and 50 mg doses of daridorexant—the company’s dual orexin receptor antagonist (DORA)—in pediatric...

March 30, 2026

Developments

FDA grants accelerated approval of Rocket’s KRESLADI for pediatric LAD-I

Rocket Pharmaceuticals (NASDAQ: RCKT) has announced FDA approval of KRESLADI, an autologous hematopoietic stem cell-based gene therapy indicated for the treatment of pediatric patients with severe leukocyte adhesion...

March 27, 2026

Developments

FDA clears Lantern/Starlight’s IND for trial of STAR-001 in pediatric cancer

Lantern Pharma (NASDAQ: LTRN) and its subsidiary, closely held Starlight Therapeutics, have announced FDA clearance of the investigational new drug (IND) application for STAR-001, in a planned Phase 1 pediatric clinical...

March 27, 2026

Developments

Radiopharm doses first patient in Phase 1 prostate cancer study

Radiopharm Theranostics (ASX: RAD) has dosed the first patient in its Phase 1 trial of RAD 402, a monoclonal antibody targeting KLK3 radiolabelled with Terbium 161 for advanced prostate cancer. The study will evaluate...

March 27, 2026

Developments

Profound congratulates Texas Prostate’s 100th TULSA Procedure milestone

Profound Medical (NASDAQ:PROF; TSX:PRN) has announced that Texas Prostate, led by Dr. James Cochran, has achieved its 100th TULSA Procedure performed in Dallas Medical Center’s state-of-the-art MRI suite. “Having...

March 27, 2026

Developments

NextPlat expands reach through collaboration with HealthWarehouse.com

NextPlat (NASDAQ: NXPL; NXPLW) has announced a collaboration with HealthWarehouse.com (OTCQB: HEWA) to enable nationwide fulfillment of prescription and over-the-counter (OTC) products. According to NextPlat, the...

March 26, 2026

Developments

Firefly confirms public-private partnership with DoW

Firefly Neuroscience (NASDAQ: AIFF) has announced a partnership with the Department of War (DoW) to support the assessment and treatment of active-duty U.S. service members and veterans suffering from post-traumatic...

March 26, 2026

Developments

IMUNON’s Phase 2 data shows OS increase in women with advanced ovarian cancer

IMUNON (NASDAQ: IMNN) has announced final clinical data from the completed Phase 2 OVATION 2 clinical trial evaluating IMNN-001 in combination with standard of care neoadjuvant and adjuvant chemotherapy (N/ACT) showing...

March 25, 2026

Developments

Amplia reports more responses and improved OS in pancreatic cancer trial

Amplia Therapeutics (ASX: ATX; OTCQB: INNMF) has announced data from the ongoing ACCENT clinical trial of narmafotinib combined with chemotherapy in advanced pancreatic cancer showing a median overall survival (OS) of...

March 23, 2026

Developments

Bioxytran completes $1.2 million private placement

Bioxytran (OTC: BIXT) has announced that it has completed a private placement financing on March 18, 2026, resulting in gross proceeds of approximately $1.2 million. In connection with the financing, the company issued...

March 20, 2026

Developments

Co-Diagnostics inks agreement to expand distribution across South Asia

Co-Diagnostics (NASDAQ: CODX) has signed an agreement for closely held CoSara Diagnostics—the Indian joint venture between Co-Dx and Ambalal Sarabhai—to significantly expand its commercial and distribution territory...

March 20, 2026

Subscribe